Medication | Comments
--- | ---
Vivitrol (naltrexone) | IM injection

**OVERRIDE(S)**

Prior Authorization of Benefits

**APPROVAL DURATION:**

6 months

**APPROVAL CRITERIA:**

Injectable naltrexone (Vivitrol) may be approved for the treatment of alcohol dependence when the following criteria have been met:

I. Individual is being treated for alcohol dependence; **AND**

II. Individual has abstained from alcohol for at least 7 days in an outpatient setting prior to treatment initiation; **AND**

III. Individual has had an initial response and tolerates oral naltrexone (Revia), but is not able to comply with daily dosing; **AND**

IV. Individual is not actively drinking at the time of initial injectable naltrexone (Vivitrol) administration; **AND**

V. Individual actively participates in a comprehensive rehabilitation program that includes psychosocial support; **AND**

VI. Individual has none of the following:

A. Currently on opioid analgesics
B. Currently physiologically dependent on opioids
C. Currently in acute opioid withdrawal
D. Failed the naloxone challenge test
E. A positive urine screen for opioids
F. Acute hepatitis
G. Liver failure
H. Previous hypersensitivity to naltrexone, 75:25 polylactide-co-glycolide (PLG), carboxymethylcellulose or any other component of the diluent

Injectable naltrexone (Vivitrol) **may be approved** for the prevention of relapse to opioid dependence following detoxification when the individual:

I. Is being treated for opioid dependence; **AND**

II. Has had an initial response and tolerates oral naltrexone (Revia) but is unable to comply with daily dosing; **AND**

III. Has successfully completed an opioid detoxification program; **AND**

IV. Has been opioid-free (including buprenorphine and methadone) for at least 7 days prior to initiating treatment with naltrexone (Vivitrol) injection; **AND**

V. Actively participates in a comprehensive rehabilitation program that includes psychosocial support; **AND**

VI. Patient has none of the following: **OR**

A. Currently on opioid analgesics for pain management; **OR**
B. Currently in acute opioid withdrawal; OR
C. A positive urine screen for opioids; OR
D. A failed naloxone challenge test; OR
E. Acute hepatitis; OR
F. Liver failure; OR
G. Previous hypersensitivity to naltrexone, 75:25 polylactide-co-glycolide (PLG), carboxymethylcellulose or any other component of the diluent.

May not be approved:
Injectable naltrexone (Vivitrol) **may not be approved** for the treatment of alcohol dependence or opioid dependence when the criteria above are not met.

Injectable naltrexone (Vivitrol) **may not be approved** for the treatment of diagnoses other than alcohol dependence and opioid dependence.